Skip navigation |

Daclatasvir recommended for combi' HCV treatment by EMA

The European Medicines Agency's committee for medicinal products for human use has recommended that daclatasvir be granted approval for use in combination for the treatment of hepatitis C.

The NS5A inhibitor will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.

Daclatasvir which also goes by the brand name Daklinza has been developed by Bristol-Myers Squibb.